Statement by the Technical Consultative Committee (TCC) of APOC in
response to the article published in the Lancet by Osei-Atweneboana MY,
Eng JKL, Boakye D, et al, vol 369 June 16, 2007.
Ivermectin (Mectizan)
remains effective for onchocerciasis (river blindness) control
The control of onchocerciasis (River Blindness) through the
Onchocerciasis Control Programme (OCP) in West Africa and the African
Programme for Onchocerciasis Control (APOC), with unwavering commitment
from affected communities, national governments, non-governmental
development organizations and an international donor collaboration
involving both the private and public sectors, is widely recognized as
one of the paramount public health successes in the developing world.
For 20 years the scourge of river blindness has been successfully
controlled through regular treatments with ivermectin, alleviating
poverty and improving the lives of millions of people in Africa. The
publication by Osei et al1 in the Lancet suggesting that ‘resistant
adult parasite populations which are not responding as expected to ivermectin (Mectizan®) are emerging’, has generated public concern.
The Technical Consultative Committee (TCC) of APOC, after careful
review, concluded that the study findings are not conclusive and that
possibility of other explanations exist that are not related to
Ivermectin resistance. TCC, therefore, recommended surveys to clarify
the situation in the field within the next 6 months. Furthermore, TCC
stressed that the study by Osei et al, as well as other recent studies
in Africa, provided compelling evidence that ivermectin is as efficient
a microfilaricide today as it was in 1987 when its large scale use in
onchocerciasis control was initiated. The TCC therefore strongly
recommended the continuation of the current strategy for control of
onchocerciasis through annual treatment with ivermectin.
The committee recognizes that population-wide treatment with a single
anti-parasitic drug brings the risk of emergence of resistance and it
will continue to monitor the effectiveness of ivermectin as the
operational control tool. TCC supports the continuation of basic and
applied research for better monitoring tools for potential appearance of
ivermectin resistance as well as research for new methods for control,
including a safe field-suitable macrofilaricidal drug.
1Osei-Atweneboana MY, Eng JKL, Boakye D, et al. Prevalence and
intensity of Onchocerca volvulus infection and efficacy of ivermectin in
endemic communities in Ghana: a two-phase epidemiological study. Lancet
369, 2021-2029, 2007
|